gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

First line therapy of metastatic colon cancer with 5-FU, folinic acid and bevacizumab in chronic renal failure: Complete remission in a patient with advanced colon cancer undergoing hemodialysis

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Christina Jochims - Klinische Onkologie am Nationalen Centrum für Tumorerkrankungen, Heidelberg, Deutschland
  • Axel Ring - Innere Medizin, Abteilung IV, Heidelberg
  • Wolfgang Stremmel - Innere Medizin, Abteilung IV, Heidelberg
  • Dirk Jäger - Klinische Onkologie am Nationalen Centrum für Tumorerkrankungen, Heidelberg
  • Thomas Herrmann - Klinische Onkologie am Nationalen Centrum für Tumorerkrankungen, Heidelberg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPE234

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk344.shtml

Published: March 20, 2006

© 2006 Jochims et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

So far, little is known about the efficiency and toxicity of chemotherapy in patients with metastatic colorectal cancer undergoing hemodialysis due to chronic renal failure. The monoclonal antibody bevacizumab (Avastin™) directed against the vascular endothelial growth factor significantly improves the outcome of patients with metastatic colorectal cancer when combined with 5-FU / FA in first line therapy without enlarging chemotherapy associated adverse effects. We present a case of a 79-year-old patient undergoing hemodialysis, who was diagnosed with a peritoneal metastasis four years after diagnosis of colon cancer. The patient was treated with chemotherapy according to the MAYO protocol (5-FU / FA bolus protocol) in combination with bevacizumab. After 6 cycles of 5-FU / FA and 12 administrations of bevacizumab, complete remission was achieved. The treatment was well tolerated, no side effects >WHO grade II occured. In conclusion, chemotherapy with 5-FU / FA according to the MAYO protocol in combination with bevacizumab is effective and safe in patients with chronic renal failure undergoing hemodialysis.